According to a report by BioSpace, Astellas Pharma has announced the submission of a “New Drug Application” (in the US) and a “Marketing Authorisation Application” (in UK) for mirabegron for the treatment of overactive bladder (OAB) associated with symptoms of urgency, urinary frequency, and urge urinary incontinence.

Mirabegron is a once daily oral selective B3-adrenoceptor agonist. Mirabegron is a selective beta-3 adrenoceptor agonist. It activates beta-3 adrenoceptor on the detrusor muscle of the bladder to facilitate filling of the bladder and storage of urine. The company claims that “unlike other OAB treatments, mirabegron works by improving the storage capacity of the bladder without affecting voiding contractions”.

The applications have been based on positive outcomes from phase III conference report (previously reported on the NeLM) – please see link below.